Mereo BioPharma

MREO · Nasdaq · United Kingdom

Share price · MREO

$0.29-0.02 (-7.57%) 3M

close as of 2026-11-18 · 24h delayed · vol 864K (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MREO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Sep 2026+7.6%

    Nothing announced by MREO that day or the session before.

  2. 11 Sep 2026+14.5%

    Nothing announced by MREO that day or the session before.

  3. 11 Aug 2026+12.2%
  4. 31 Jul 2026+8.8%

    Nothing announced by MREO that day or the session before.

  5. 2 Jun 2026+10.1%
  6. 26 May 2026+20.1%

    Nothing announced by MREO that day or the session before.

  7. 20 May 2026+18.9%

    Nothing announced by MREO that day or the session before.

  8. 6 May 2026-15.1%

    Nothing announced by MREO that day or the session before.

  9. 4 May 2026+10.4%

    Nothing announced by MREO that day or the session before.

  10. 9 Jan 2026+28.6%

    Nothing announced by MREO that day or the session before.

Share of unusual movement by asset

For each asset, the share of MREO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
alvelestat
events and moves
1shown from 8 days
setrusumab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—39%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—47%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
SclerostinMonoclonal antibody
Osteogenesis Imperfecta
Phase 2
Neutrophil elastaseSmall molecule
Chronic Obstructive Pulmonary DiseaseAlpha-1 Antitrypsin Deficiency

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
setrusumabPhase 3Osteogenesis Imperfecta
Est. primary completion 2027-01 · NCT06636071 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 December 2025Topline resultsetrusumabPhase 3 Orbit (NCT05125809) and Cosmic of setrusumab did not meet their primary fracture-rate endpoints

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.8M$2.1M$26M$5.9M-$4.0M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$1.8M$30M$7.0M-$6.0M operating cash flowreport ↗
2026-Q1—$4.8M$36M$6.7Mreport ↗
2025-Q3$0$4.3M$49M$7.0M-$7.3M operating cash flowreport ↗
2025-Q2$0.5M$5.4M$56M$15M-$7.7M operating cash flowreport ↗
2025-Q1—$3.9M$62M$13M-$8.3M operating cash flowreport ↗
2024-Q3$0$3.2M$81M$15M-$7.5M operating cash flowreport ↗
2024-Q2$0$5.0M$87M$12M-$7.9M operating cash flowreport ↗
2024-Q1$0$4.0M$49M$8.9M-$8.0M operating cash flowreport ↗
2023-Q3$0$3.6M—$6.5M$2.7M operating cash flowreport ↗
2023-Q2$9.0M$3.7M—$1.8M-$7.8M operating cash flowreport ↗
2023-Q1$0$5.3M—$12M-$9.3M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.5M$18M$41M$10M-$31M operating cash flowreport ↗

Mereo BioPharma reported FY2025 revenue of $0.5M versus $0M in the prior year, with R&D spend of $17.77M, down 15.1% YoY, and cash and equivalents of $40.99M as of December 31, 2025. The company recorded a net loss of $41.88M for the year.

Management guided that existing cash is expected to fund operations into mid-2027. The Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta missed their primary endpoints but achieved high statistical significance on the key secondary endpoint of bone mineral density, with further analyses ongoing. Alvelestat Phase 3 site feasibility work is complete ahead of a planned ~220-patient pivotal trial, and partner Ashibio plans to initiate a Phase 2 study of vantictumab in osteopetrosis in the second half of 2026.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$21M$70M$11M-$33M operating cash flowreport ↗
2023-FY$10M$17M$57M$7.4M-$21M operating cash flowreport ↗
2022-FY$0$29M$68M$11M-$49M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-02-26WYZGA MICHAEL S · directorAward / grant (derivative)66,000——Form 4
2026-02-26Jenkins Annalisa · directorAward / grant (derivative)66,000——Form 4
2026-02-26PAKIANATHAN DEEPIKA · directorAward / grant (derivative)66,000——Form 4
2026-02-26Bender Jeremy · directorAward / grant (derivative)66,000——Form 4
2026-02-26Ekblom Anders · directorAward / grant (derivative)66,000——Form 4
2026-02-26Shames Daniel · directorAward / grant (derivative)66,000——Form 4
2026-02-26Yoskowitz Marc J · directorAward / grant (derivative)66,000——Form 4
2026-02-26Jacquet Pierre · directorAward / grant (derivative)66,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 63 reporting institutions held 75.4M shares ($24.8M, 47.2% of shares outstanding).

#InstitutionSharesValue
1Rubric Capital Management LP15,307,347$5.1M
2EcoR1 Capital, LLC13,368,855$4.4M
3683 Capital Management, LLC12,000,000$4.0M
4BANK OF AMERICA CORP /DE/8,195,287$2.7M
5Defilade Capital Management, L.P.7,558,756$2.5M
6Newtyn Management, LLC7,079,056$2.3M
7MILLENNIUM MANAGEMENT LLC3,559,103$1.2M
8Tejara Capital Ltd2,037,520$672K
9UBS Group AG1,490,128$492K
10Wealthspire Advisors, LLC796,036$263K
11MARSHALL WACE, LLP686,987$227K
12GROUP ONE TRADING LLC335,827$111K
13Rangeley Capital, LLC329,200$109K
14BlackRock, Inc.302,991$100K
15Knott David M Jr300,337$99K